on the whole how is bathing ghat coliform
On the whole, when evaluating the bathing ghats across the region, fecal coliform levels present a highly mixed picture. The water quality does not universally pass or fail, but rather fluctuates dramatically depending on the exact location of the ghat and the season. [1, 2, 3, 4, 5]
A clear split exists between official baseline testing and real-time localized realities on the banks:
1. The Official Baseline (Mid-Stream & Main Channels)
- Often Within Legal Limits: When the Central Pollution Control Board (CPCB) or state agencies pull routine regulatory samples from the central, fast-flowing main channels of the river, the fecal coliform counts frequently hover between 700 to 2,200 MPN / 100 mL. [1]
- The Verdict: Because this meets the maximum statutory safety ceiling for primary outdoor bathing (≤ 2,500 MPN / 100 mL), official tracking charts generally classify the overall mainstream flow past major tourist stretches as technically "fit for bathing". [1, 2, 3, 4]
2. The Localized Shoreline Reality (Where People Actually Bathe)
- Significant Pollution Plumes: Independent testing, court-ordered environmental audits, and local ecological groups like the Sankat Mochan Foundation (SMF) paint a much more challenging picture closer to the actual shoreline. [1]
- The Points of Impact: Near the southern edge of Varanasi (around areas like Samne Ghat or Nagwa) or directly downstream of local urban canals, fecal coliform bacteria levels regularly spike exponentially—sometimes logging numbers into the hundreds of thousands or millions MPN / 100 mL. [1, 2, 3]
- The Verdict: Because water moves slower near the shore and steps, localized pockets remain heavily contaminated with pathogen indicators due to continuous neighborhood graywater runoff. [1, 2]
3. The Seasonal Spike Factors
If you look at the system year-round, coliform levels shift predictably based on two major catalysts:
===================================================================
- The Verdict: Because water moves slower near the shore and steps, localized pockets remain heavily contaminated with pathogen indicators due to continuous neighborhood graywater runoff. [1, 2]
so is it safe for millions who bathe there?
===================================================================
From a strict medical and scientific standpoint, no, it is not entirely safe, and taking a dip carries a persistent risk of waterborne illnesses. However, from a practical and cultural standpoint, millions continue to bathe daily because the risk rarely manifests as acute, widespread medical emergencies. [1, 2, 3]
The contradiction between scientific unsafety and mass public survival comes down to three main factors:
1. The Real Medical Risks
Because shoreline fecal coliform levels frequently exceed safe swimming limits, medical researchers from institutions like the Institute of Medical Sciences, BHU document that swimmers are routinely exposed to elevated levels of pathogens. The most common health outcomes are not universally fatal, but include: [1, 2, 3, 4]
- Skin and Eye Infections: Dermatitis, fungal rashes, and severe conjunctivitis from direct contact with contaminated shoreline water.
- Gastrointestinal Distress: Minor diarrhea, cramping, and low-grade viral gastroenteritis, which occurs primarily when bathers accidentally swallow the river water.
- Waterborne Diseases: Elevated potential exposure to typhoid, hepatitis A, and dysentery. [1, 2, 3, 4, 5]
2. Why Millions Bathe Without Mass Illness
Despite the high bacterial counts, you do not see millions of people falling critically ill every day on the ghats. Epidemiologists and local observers attribute this to several factors:
- Acquired Immunity: The vast majority of everyday bathers are local residents or regional pilgrims who have been exposed to the local water and soil environment since childhood. Their immune systems have developed strong antibodies against common regional strains of E. coli and gastrointestinal bacteria. [1, 2]
- The "Dip" Mechanics: Most pilgrims practice a short, ritualistic immersion—dipping into the water for just a few seconds without swimming, playing, or purposefully ingesting the water. This significantly minimizes their actual internal exposure to pathogens. [1, 2]
- The Bacteriophage Phenomenon (The "Ganga Action"): Scientifically, the Ganges possesses unique ecological properties, including an exceptionally high concentration of bacteriophages (viruses that naturally target and destroy specific harmful bacteria). While phages cannot completely sterilize heavily polluted water, they help accelerate the river’s natural self-cleaning cycle in the fast-moving central channels. [1, 2, 3, 4]
3. Who Faces the Highest Risk?
The safety equation changes drastically depending on who is entering the water: [1]
- High Risk: Domestic and international tourists, infants, and individuals with compromised immune systems face a high risk of immediate illness because their bodies lack baseline immunity to these local waterborne microbes.
- Low Risk: Local boatmen, priests, and long-term residents display very low rates of acute illness from daily contact. [1, 2, 3, 4]
Practical Safety Rules for Visitors
If you or anyone you know plans to visit the Varanasi or Ghazipur ghats and wants to participate safely, environmental health experts recommend a few basic rules:
- Avoid bathing near the Assi or Varuna confluences where urban runoff is highest. Stick to central, fast-flowing ghats like Dashashwamedh.
- Never swallow the water or use it to rinse your mouth or eyes.
- Take a fresh-water shower immediately after stepping off the ghats to rinse pathogens off your skin. [1, 2, 3, 4, 5]
Would you like to know about how local hospitals track seasonal waterborne cases, or learn more about the bacteriophages that naturally fight pollution in the river?
========================================================================
- Never swallow the water or use it to rinse your mouth or eyes.
but many do it
========================================================================
The fact that millions of people regularly sip Ganga jal (Ganges water) or use it to rinse their faces without immediately falling ill is one of the most fascinating cultural and scientific intersections in India.
The public continues this practice due to a powerful combination of profound spiritual faith, community-wide acquired immunity, and a unique geological phenomenon that physically alters how the river handles bacteria.
1. Faith Overrides the Visual Reality
Culturally, Hindus view the Ganges not just as a body of water, but as a living goddess (Ganga Maiya). In traditional theology, the river is inherently pure (pavitra) and possesses a spiritual capacity to cleanse sins and heal souls. Because of this profound spiritual conviction, the physical presence of mud, silt, or modern urban runoff is viewed by believers as external, surface-level impurities that cannot corrupt the inner divine nature of the holy water. Sip-taking and eye-rinsing are deeply ingrained, multi-generational rituals that people perform as acts of absolute devotion. [1, 2, 3, 4]
2. The Built-In "Shield" of Acquired Immunity
From a biological perspective, if an international tourist or a traveler from another region were to sip the water at a crowded shoreline, they would likely suffer from acute gastroenteritis within 24 to 48 hours. [1, 2]
However, the millions of pilgrims and locals who do it regularly have a massive advantage: acquired immunity. Having lived in the regional environment and consumed local food and water since infancy, their digestive tracts have built an incredibly resilient gut microbiome. Their immune systems recognize and neutralize standard levels of localized E. coli and other coliform bacteria before those pathogens can trigger a severe medical emergency. [1]
3. The Science: The River’s Secret "Antibiotic" Weapon
What many people describe as a miracle actually has a verified scientific foundation. Over a century ago, in 1896, British bacteriologist Ernest Hankin discovered that cholera bacteria died incredibly fast when placed in Ganges water. Modern institutions—like the National Environmental Engineering Research Institute (NEERI)—have since proven why: [1]
- Massive Bacteriophage Population: The Ganges contains up to 3 times more bacteriophages than typical freshwater rivers. Phages are natural "killer viruses" that do not harm humans, but specifically target, attack, and literally eat harmful bacteria like Escherichia coli and Vibrio cholerae. [1, 2, 3]
- The Rupture Mechanism: Microscopic imagery shows that when E. coli enters the river, these native phages latch onto the bacterial cell walls, replicate inside them, and cause the harmful cells to burst open and disintegrate. [1]
- High Dissolved Oxygen: Due to its rapid descent from the high rocks of the Himalayas, the river water retains exceptionally high levels of dissolved oxygen, which significantly accelerates its natural self-cleansing capacity. [1, 2]
The Modern Warning Limit
While these phages work around the clock to clean the river, environmental scientists warn that the system has an breaking point. Because of massive urban population booms since your 1970 visit, the pure volume of human greywater poured into the banks sometimes overwhelms the natural population of phages. [1, 2, 3]
========================================================================
share details on how these native bacteriophages are being studied to create new medical antibiotics
========================================================================
The study of Ganges bacteriophages has transitioned from historical curiosity into frontline biomedical research aimed at solving Antimicrobial Resistance (AMR). As standard pharmaceutical antibiotics lose efficacy against drug-resistant "superbugs," major medical institutions are actively sequencing, isolating, and testing these native viruses as direct therapeutic replacements. [1, 2, 3, 4]
The ongoing scientific research into creating new medical therapies from Ganges phages focuses on several key strategies: [1]
1. Targeting the Critical "ESKAPEE" Superbugs
Major research bodies—such as India's National Environmental Engineering Research Institute (CSIR-NEERI) in collaboration with the National Chemical Laboratory (CSIR-NCL)—have mapped the viral ecosystems of the river. They have isolated distinct lytic phages that successfully target the highly lethal, drug-resistant ESKAPEE pathogen group. This group includes: [1, 2]
- Enterococcus faecium, Staphylococcus aureus, and Klebsiella pneumoniae.
- Pseudomonas aeruginosa and Acinetobacter baumannii. [1, 2, 3]
2. Clinical Success at Leading Indian Medical Institutes
Top-tier research facilities have extracted specific phages from Ganges water collected across the Varanasi and Himalayan stretches to prove their efficacy in laboratory and clinical settings: [1, 2, 3]
- The AIIMS Delhi Breakthrough: The microbiology department at the All India Institute of Medical Sciences (AIIMS) successfully isolated a novel lytic phage named AIIMS-Pa-A1 from the river. In controlled trials, this virus proved more effective than top-tier pharmaceutical antibiotics (like ceftazidime or amikacin) at completely obliterating drug-resistant Pseudomonas aeruginosa. This pathogen is a leading cause of fatal bloodstream infections, severe burn wound complications, and diabetic foot ulcers. [, 2, 3, 5]
- The Zebrafish Efficacy Models: Research tracking Klebsiella pneumoniae (a superbug causing severe hospital pneumonia) showed that administering a combination of Ganges phages alongside standard antibiotics resulted in a 6-log decline in bacterial colonies. Animal trials in zebrafish models proved that the therapy targeted only the dangerous bacteria without causing any toxic side effects to the host’s liver or brain. [1]
3. Engineering "Phage Cocktails" and Pure Proteins
Scientists are moving past using raw water or single viruses. Because bacteria can rapidly evolve to resist a single type of virus, researchers are developing complex medical formulations: [1, 2, 3]
- Phage Cocktails: Laboratories mix several genetically distinct Ganges phages into a single therapeutic mixture. If a superbug mutates to block one virus, the other strains in the cocktail still breach the bacterial cell wall. [1]
- Genetically Cloning Lysin Proteins: In a high-profile study backed by the National Mission for Clean Ganga (NMCG), researchers at IIT Roorkee successfully isolated a "super-phage" and decoded its lysine gene. They cloned this gene to produce pure, concentrated lysine proteins. This enzyme acts like a chemical drill, dissolving bacterial cell walls on contact. It can be mass-manufactured into standard pharmaceutical creams or liquids without needing to inject live viruses into patients. [1, 2, 3, 4, 5]
4. Eradicating Persistent Biofilms
One of the hardest challenges in modern medicine is a biofilm—a slimy, protective shield that colonies of bacteria build over themselves on surgical implants, catheters, or open wounds. Standard antibiotics cannot penetrate this slime layer. [1, 2, 3, 4]
Recent studies published in journals like ScienceDirect have isolated novel broad-spectrum phages (such as the Tequatrovirus genus) from the pristine upper stretches of the Ganges. These phages produce specific enzymes that actively chew through the protective biofilm matrix, reducing the inner bacterial population by over 99% within 24 hours. [1, 2, 3, 4]
If you'd like to dive deeper into this medical transition, let me know:
- Would you like details on how phage therapy is administered to patients (topical creams vs. intravenous lines)?
- Are you interested in the regulatory challenges the World Health Organisation (WHO) faces in approving these living viruses for global clinical use?
========================================================================
ME
- 1=regulatory challenges the World Health Organisation (WHO) faces in approving these living viruses for global clinical use?
2-also when these treatment will be available on open market shops?
====================================================
3=also when-
=======
This enzyme acts like a chemical drill, dissolving bacterial cell walls on contact. It can be mass-manufactured into standard pharmaceutical creams or liquids without needing to inject live viruses into patients.
========================================================================
The global health and regulatory landscape reveals that true "living" phage therapies are not yet available in open-market pharmacies. Currently, they are heavily restricted to specialized hospitals and compassionate-use frameworks. [1, 2, 3]
However, non-living phage lysin creams and topical liquids are moving much faster down the development pipeline. [1]
⚖️ Regulatory Challenges Faced by the WHO and Global Agencies
The World Health Organization (WHO) and major bodies like the FDA face unique, unprecedented challenges when trying to evaluate living viruses under rules written for static chemicals: [1, 2]
- The "Moving Target" Dilemma (Evolution): Traditional drugs never change their chemical structure after manufacturing. Living phages are biological entities that can replicate, mutate, and evolve inside the human body. Regulators struggle to approve a drug whose genetic sequence might subtly shift mid-treatment. [1]
- The Specificity Bottleneck: Broad-spectrum antibiotics kill thousands of bacterial strains at once. A single phage is hyper-specific, often killing only one precise strain of E. coli found in one specific patient. Standard randomized, large-scale clinical trials require a single, unchanging drug formula, making custom "personalized phage cocktails" incredibly difficult to standardize. [1, 2, 3, 4, 5]
- Toxin Release Risks: When phages attack superbugs, they cause the bacterial cell walls to burst open violently. This rapid destruction releases massive amounts of internal bacterial debris (endotoxins) directly into the patient's bloodstream, which can trigger severe inflammatory responses or septic shock if not strictly monitored. [1]
- Mass Production Consistency (GMP): Under Good Manufacturing Practices (GMP), factories must guarantee every batch of medicine is identical. Because phages must be grown inside live, potentially hazardous host bacteria, purifying the virus to ensure zero bacterial contamination is a highly complex, expensive process. [1, 2, 3, 4]
🛒 When Will These Reach Open-Market Shops?
The timeline for buying these products off the shelf varies drastically based on whether you are looking for living viruses or engineered proteins: [1]
| Product Type | Market Availability Timeline | Current Access Method |
|---|---|---|
| Non-Living Lysin Creams / Liquids (The "Chemical Drills" mentioned earlier) | Expected around 2028 – 2030 | Currently undergoing Phase II and Phase III clinical testing for skin and wound infections. |
| Living Phage Intravenous (IV) Injections (For severe, internal blood/lung superbugs) | Expected post-2032+ (Strictly prescription/hospital only) | Restricted to emergency "compassionate use" cases when all known pharmaceutical antibiotics have failed. |
| Over-the-Counter "Phage Supplements" (Sold on the web or in wellness shops) | Available Now | Sold purely as "dietary supplements" for gut health, but these are legally barred from claiming they cure medical infections. |
Why Non-Living Lysins Will Arrive First
Engineered lysin creams—the proteins isolated from Ganges phages—will bypass the strict "living drug" laws. Because these proteins are non-living, stable, and easily manufactured in standard labs, regulatory bodies can test and approve them just like traditional topical ointments. They are highly likely to appear on open market shelves by the end of the decade as targeted treatments for diabetic ulcers, severe acne, and burn wounds. [1]
If you want to track how these progress, let me know:
- Would you like to know which specific biotech companies are leading the current Phase III trials?
- Are you interested in learning how countries like Georgia or Russia currently manage over-the-counter phage access? [1, 2]
Let me know how you would like to proceed!
========================================================================
ME interested in learning how countries like Georgia or Russia currently manage over-the-counter phage access
2=like to know which specific biotech companies are leading the current Phase III trials?
========================================================================
Over-the-counter (OTC) phage availability and advanced clinical trials represent two entirely different regulatory pathways for bacteriophage therapy. While Eastern Europe relies on decades of traditional, broad-spectrum access, Western biotech companies are navigating highly controlled, modern regulatory frameworks to bring targeted phage treatments to market. [1, 2, 3]
Part 1: OTC Phage Access in Georgia and Russia
In Georgia and Russia, bacteriophages are not viewed as experimental anomalies; they are standard, licensed pharmaceutical products regulated by national health authorities and sold directly to consumers alongside standard antibiotics. [1, 2, 3, 4, 5]
🇬🇪 Georgia's Framework
- The Epicentre: The global model for phage access is centered around the George Eliava Institute in Tbilisi. [1]
- Commercial Availability: Its commercial manufacturing arm, Eliava BioPreparations, produces standardized, broad-spectrum OTC "phage cocktails". [1, 2]
- Primary OTC Products: You can walk into a standard Georgian pharmacy and purchase products like PioBacteriophage (targeting Staphylococcus, Streptococcus, Pseudomonas, E. coli, and Proteus) and IntestiBacteriophage (targeting gastrointestinal pathogens like Salmonella and Shigella) without a prescription. [1]
- The Clinical Exception: While broad cocktails are sold OTC, complex or chronic antibiotic-resistant infections are routed directly through the Eliava Phage Therapy Center, where doctors sequence the patient's specific bacterial strain and blend a customized, prescription-only phage formulation. [1, 2, 3, 4, 5]
🇷🇺 Russia's Framework
- Mass Production: Phage production is fully industrialized under Microgen, a massive state-owned pharmaceutical subsidiary of the Rostec enterprise.
- Pharmacy Access: Microgen mass-produces liquid ampoules, tablets, sprays, and gels that are distributed nationwide to public hospitals and retail pharmacies. [1]
- Standardized Blends: Russian consumers regularly purchase OTC preparations like Sexataphage or Enko to treat common ailments like acne, dysentery, surgical wounds, and respiratory infections. [1, 2, 3]
- The Regulatory Loophole: Because these products were integrated into the Soviet pharmacopeia before modern Western standards for Randomized Controlled Trials (RCTs) were established, they maintain grandfathered approval status.
Part 2: Biotech Companies Leading Phase II/III Trials
In the West, regulatory bodies like the FDA and EMA do not recognize grandfathered Soviet data. To achieve market authorization, Western biotechs must prove efficacy via rigorous clinical pipelines. [1, 2, 3, 4]
Because phages are living biological entities that evolve and target highly specific strains, setting up traditional Phase III trials is incredibly difficult. Only a couple of pioneering clinical-stage biotech companies have reached late-stage pivotal trials: [1, 2, 3]
1. Locus Biosciences
- The Innovation: Locus Biosciences develops CRISPR-engineered phages. Unlike natural phages, their lead asset (LBP-EC01) is loaded with "CRISPR-Cas3 molecular scissors" that actively shred the bacterial DNA, preventing the bacteria from developing resistance.
- The Trial: They are leading the ELIMINATE trial (NCT05488340), which is a combined Phase 2/3 trial heavily funded by a $24M+ contract from BARDA.
- Target Pathogen: It targets multi-drug resistant Escherichia coli (E. coli) causing recurrent or complicated Urinary Tract Infections (UTIs). [1, 2, 3, 4, 5]
2. Armata Pharmaceuticals
- The Innovation: Led by CEO Dr. Deborah Birx, Armata Pharmaceuticals focuses on highly purified, non-engineered, pathogen-specific natural multi-phage cocktails manufactured in-house under strict current Good Manufacturing Practices (cGMP).
- The Trial: Following successful Phase IIa data from their "diSArm" study, Armata officially submitted its Phase III superiority study protocol to the FDA for its lead candidate, AP-SA02. The company is actively preparing clinical trial materials to initiate this registration-enabling Phase III trial.
- Target Pathogen: AP-SA02 is an intravenous cocktail targeting life-threatening, complicated bacteremia (bloodstream infections) caused by Staphylococcus aureus, including superbug strains like MRSA. [1, 2, 3]
3. BiomX Inc.
- The Current Status: BiomX is a major clinical-stage player that recently advanced its pipeline by acquiring Adaptive Phage Therapeutics. While they are highly visible leaders in the field, their primary candidate (BX004 for treating chronic Pseudomonas aeruginosa lung infections in Cystic Fibrosis patients) is currently paving its way through robust Phase II trials rather than an active Phase III. [1, 2, 3, 4]
If you want to look closer at either side of this global landscape, let me know. I can detail how to legally travel to Georgia as a medical tourist for custom phage treatment, or break down the specific scientific mechanisms of CRISPR-Cas3 used in Locus's advanced trials. [1, 2]
========================================================================
me
break down the specific scientific mechanisms of CRISPR-Cas3 used in Locus's advanced trials
2=Russian consumers regularly purchase OTC preparations- will this cause problems for FDA ALLOWED RESEARCH--SUCH AS CROSS RESISTANCE?
3= FDA RESEARCH CAN USE INFORMATION FROM RUSSIA AND GEORGIA ABOUT THE EFFECT/ALLERGY ETC
3= FDA RESEARCH CAN USE INFORMATION FROM RUSSIA AND GEORGIA ABOUT THE EFFECT/ALLERGY ETC
========================================================================
The integration of advanced gene-editing tools like CRISPR into phage therapy represents a major technological leap, designed specifically to overcome the regulatory and biological hurdles seen in traditional Eastern European phage applications. [1]
Part 1: Scientific Mechanism of CRISPR-Cas3 in Locus Biosciences' Trials
While the famous CRISPR-Cas9 system acts like precise "molecular scissors" to cut DNA at one specific spot, CRISPR-Cas3 acts like a molecular "Pac-Man." Locus Biosciences engineered this system to completely obliterate bacterial pathogens rather than modify them. [1, 2]
The precision mechanism unfolds in a multi-step process:
[Phage Injects DNA] ──> [gRNA Finds Target] ──> [Cas3 Recruited] ──> [Genome Shredded (Pac-Man)]
- Step 1: The Trojan Horse Delivery: Locus takes a natural, non-engineered lytic bacteriophage and inserts the genes for the Cas3 protein and custom guide RNAs (gRNA) directly into the phage genome. The phage attaches to the target bacterium (like E. coli) and injects this engineered DNA. [1, 2]
- Step 2: Homed Targeting: Once inside, the bacterial cell's own machinery mistakenly transcribes and translates the CRISPR-Cas3 components. The custom gRNA scans the bacterial chromosome to find and bind to a highly specific, vital DNA sequence unique to that pathogen.
- Step 3: Unidirectional Shredding ("The Pac-Man Effect"): Once the gRNA locks onto the target, it recruits the Cas3 enzyme. Unlike Cas9, which stops after making a single double-stranded cut, Cas3 acts as a molecular motor and exonuclease. It locks onto the cut DNA, zips along the chromosome, and irreversibly chews up thousands of base pairs of bacterial DNA. [1, 2, 3, 4]
- Step 4: Dual-Action Kill System: If a bacterium suffers a standard double-stranded break, its internal repair mechanisms (like SOS repair) might fix it and create an antibiotic-resistant or phage-resistant mutant. Cas3 shreds the genome so extensively that repair is impossible, causing immediate cell death. Even if the CRISPR system fails, the natural lytic cycle of the phage takes over, replicating until the cell bursts. [1, 2, 3]
Part 2: CAN Russian/Georgian OTC Phages Cause Cross-Resistance Risks for Western FDA Research?
No, mass over-the-counter (OTC) phage usage in Russia and Georgia will not cause cross-resistance problems for US FDA-regulated clinical trials.
- The Geographic Isolation of Microbes: Bacterial resistance to phages occurs locally through the mutation or loss of specific surface receptors. Because the bacterial strains causing a urinary tract infection (UTI) in a US-based trial are geographically isolated from the strains exposed to Microgen's OTC cocktails in Moscow or Tbilisi, the resistance profiles do not mix. [1]
- Completely Different Targets: Russian OTC preparations like Sexataphage rely on standard, wild-type phages isolated decades ago. Advanced FDA-supervised trials like Locus's ELIMINATE trial use precise, engineered phages targeting exact genetic markers. A bacteria mutating its surface to evade a common Russian cocktail remains completely vulnerable to a Western engineered phage. [1]
- The Global Commuter Caveat: The only theoretical threat is "global transmission"—a patient purchasing OTC phages in Georgia, developing a highly resistant superbug strain in their microbiome, and migrating to the US. However, strict enrollment criteria for FDA trials screen out patients with recent international medical travel, neutralizing this risk.
Part 3: Can the FDA Use Historical Data from Russia and Georgia?
The US FDA cannot use historical clinical efficacy data from Russia or Georgia to grant drug approvals, but it can and does utilize their safety and toxicity data. [1]
- Why Efficacy Data is Rejected: The FDA mandates strict Randomized Controlled Trials (RCTs) under current Good Clinical Practice (GCP) standards. Much of the historical Eastern European data is observational, lacks rigorous control groups, or evaluates blended "cocktails" whose precise chemical compositions fluctuate by batch. [, 2]
- How Toxicity and Allergy Data is Used: The FDA actively reviews Eastern European literature to establish baseline human safety Profiles. Decades of widespread OTC use in Georgia and Russia prove that bacteriophages have an incredibly high therapeutic index. They are generally non-toxic, do not harm the broader human microbiome, and do not spark severe systemic allergic reactions (anaphylaxis), because they target bacterial cells, not human tissue. [1, 2, 3]
- Accelerating Phase I Approvals: This vast historical track record of safety helps Western biotech companies convince the FDA to bypass extensive, lengthy animal toxicity testing. This allows them to advance directly into Phase I/II human trials far more rapidly.
If you want to dive deeper into the regulatory landscape, let me know. I can break down the FDA's Investigative New Drug (IND) application process for phages, or detail the specific genetic sequences Locus targets in E. coli genomes. [1, 2]
No comments:
Post a Comment